# Rimini Street, Inc.: financial statements, quarterly

RMNI · Nasdaq · CIK 1635282 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rmni.md) · [Financials](/companies/rmni/financials.md) · [Filings](/companies/rmni/filings.md) · [Insiders](/companies/rmni/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rmni/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [112 d](/filings/0001635282-24-000030.md) | [107](/filings/0001635282-24-000107.md) | [103](/filings/0001635282-24-000143.md) | [105](/filings/0001635282-24-000173.md) | [114 d](/filings/0001635282-26-000014.md) | [104](/filings/0001635282-26-000042.md) | [104](/filings/0001635282-26-000056.md) | [103](/filings/0001635282-26-000074.md) | [110 d](/filings/0001635282-26-000014.md) | [105](/filings/0001635282-26-000042.md) | [111](/filings/0001635282-26-000056.md) | [112](/filings/0001635282-26-000074.md) |
| Cost of revenue | $m | [43.7 d](/filings/0001635282-26-000014.md) | [42.9](/filings/0001635282-25-000131.md) | [42.2](/filings/0001635282-25-000190.md) | [41.1](/filings/0001635282-25-000215.md) | [41.5 d](/filings/0001635282-26-000014.md) | [40.7](/filings/0001635282-26-000042.md) | [41.3](/filings/0001635282-26-000056.md) | [41.5](/filings/0001635282-26-000074.md) | [43.5 d](/filings/0001635282-26-000014.md) | [43.2](/filings/0001635282-26-000042.md) | [43.4](/filings/0001635282-26-000056.md) | [43.3](/filings/0001635282-26-000074.md) |
| Gross profit | $m | [68.4 d](/filings/0001635282-26-000014.md) | [63.8](/filings/0001635282-25-000131.md) | [60.9](/filings/0001635282-25-000190.md) | [63.5](/filings/0001635282-25-000215.md) | [72.7 d](/filings/0001635282-26-000014.md) | [63.5](/filings/0001635282-26-000042.md) | [62.9](/filings/0001635282-26-000056.md) | [61.9](/filings/0001635282-26-000074.md) | [66.3 d](/filings/0001635282-26-000014.md) | [62.3](/filings/0001635282-26-000042.md) | [67.7](/filings/0001635282-26-000056.md) | [68.8](/filings/0001635282-26-000074.md) |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001635282-26-000042.md) | [0.0](/filings/0001635282-26-000056.md) | [0.0](/filings/0001635282-26-000074.md) | not reported | [0.6](/filings/0001635282-26-000042.md) | [1.1](/filings/0001635282-26-000056.md) | [1.2](/filings/0001635282-26-000074.md) |
| Operating income | $m | [11.5 d](/filings/0001635282-26-000014.md) | [3.4](/filings/0001635282-25-000131.md) | [(0.8)](/filings/0001635282-25-000190.md) | [(49.6)](/filings/0001635282-25-000215.md) | [14.9 d](/filings/0001635282-26-000014.md) | [9.4](/filings/0001635282-26-000042.md) | [41.2](/filings/0001635282-26-000056.md) | [4.4](/filings/0001635282-26-000074.md) | [5.0 d](/filings/0001635282-26-000014.md) | [4.8](/filings/0001635282-26-000042.md) | [6.4](/filings/0001635282-26-000056.md) | [9.8](/filings/0001635282-26-000074.md) |
| Interest expense | $m | [1.4 d](/filings/0001635282-24-000030.md) | [1.3](/filings/0001635282-24-000107.md) | [1.5](/filings/0001635282-25-000190.md) | [1.6](/filings/0001635282-25-000215.md) | [1.9 d](/filings/0001635282-26-000014.md) | [1.7](/filings/0001635282-26-000042.md) | [1.6](/filings/0001635282-26-000056.md) | [1.4](/filings/0001635282-26-000074.md) | [1.4 d](/filings/0001635282-26-000014.md) | [1.3](/filings/0001635282-26-000042.md) | [1.1](/filings/0001635282-26-000056.md) | [1.0](/filings/0001635282-26-000074.md) |
| Income tax | $m | [2.0 d](/filings/0001635282-26-000014.md) | [1.7](/filings/0001635282-25-000131.md) | [0.4](/filings/0001635282-25-000190.md) | [(8.7)](/filings/0001635282-25-000215.md) | [6.3 d](/filings/0001635282-26-000014.md) | [4.3](/filings/0001635282-26-000042.md) | [10.5](/filings/0001635282-26-000056.md) | [0.7](/filings/0001635282-26-000074.md) | [3.0 d](/filings/0001635282-26-000014.md) | [0.9](/filings/0001635282-26-000042.md) | [2.6](/filings/0001635282-26-000056.md) | [3.4](/filings/0001635282-26-000074.md) |
| Net income | $m | [9.4 d](/filings/0001635282-26-000014.md) | [1.3](/filings/0001635282-25-000131.md) | [(1.1)](/filings/0001635282-25-000190.md) | [(43.1)](/filings/0001635282-25-000215.md) | [6.7 d](/filings/0001635282-26-000014.md) | [3.4](/filings/0001635282-26-000042.md) | [30.3](/filings/0001635282-26-000056.md) | [2.8](/filings/0001635282-26-000074.md) | [0.7 d](/filings/0001635282-26-000014.md) | [1.4](/filings/0001635282-26-000042.md) | [2.4](/filings/0001635282-26-000056.md) | [6.5](/filings/0001635282-26-000074.md) |
| Diluted EPS | $ per share | not reported | [0.01](/filings/0001635282-25-000131.md) | [(0.01)](/filings/0001635282-25-000190.md) | [(0.47)](/filings/0001635282-25-000215.md) | not reported | [0.04](/filings/0001635282-26-000042.md) | [0.32](/filings/0001635282-26-000056.md) | [0.03](/filings/0001635282-26-000074.md) | not reported | [0.01](/filings/0001635282-26-000042.md) | [0.03](/filings/0001635282-26-000056.md) | [0.07](/filings/0001635282-26-000074.md) |
| Basic EPS | $ per share | not reported | [0.01](/filings/0001635282-25-000131.md) | [(0.01)](/filings/0001635282-25-000190.md) | [(0.47)](/filings/0001635282-25-000215.md) | not reported | [0.04](/filings/0001635282-26-000042.md) | [0.33](/filings/0001635282-26-000056.md) | [0.03](/filings/0001635282-26-000074.md) | not reported | [0.01](/filings/0001635282-26-000042.md) | [0.03](/filings/0001635282-26-000056.md) | [0.07](/filings/0001635282-26-000074.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [115](/filings/0001635282-25-000029.md) | [129](/filings/0001635282-24-000107.md) | [134](/filings/0001635282-24-000143.md) | [119](/filings/0001635282-24-000173.md) | [88.8](/filings/0001635282-26-000014.md) | [123](/filings/0001635282-25-000131.md) | [101](/filings/0001635282-25-000190.md) | [109](/filings/0001635282-25-000215.md) | [120](/filings/0001635282-26-000074.md) | [132](/filings/0001635282-26-000042.md) | [123](/filings/0001635282-26-000056.md) | [93.3](/filings/0001635282-26-000074.md) |
| Current assets | $m | [289](/filings/0001635282-25-000029.md) | [248](/filings/0001635282-24-000107.md) | [263](/filings/0001635282-24-000143.md) | [229](/filings/0001635282-24-000173.md) | [256](/filings/0001635282-26-000014.md) | [235](/filings/0001635282-25-000131.md) | [282](/filings/0001635282-25-000190.md) | [234](/filings/0001635282-25-000215.md) | [300](/filings/0001635282-26-000074.md) | [274](/filings/0001635282-26-000042.md) | [262](/filings/0001635282-26-000056.md) | [231](/filings/0001635282-26-000074.md) |
| Total assets | $m | [394](/filings/0001635282-25-000029.md) | [351](/filings/0001635282-24-000107.md) | [367](/filings/0001635282-24-000143.md) | [344](/filings/0001635282-24-000173.md) | [369](/filings/0001635282-26-000014.md) | [343](/filings/0001635282-25-000131.md) | [397](/filings/0001635282-25-000190.md) | [353](/filings/0001635282-25-000215.md) | [423](/filings/0001635282-26-000074.md) | [397](/filings/0001635282-26-000042.md) | [384](/filings/0001635282-26-000056.md) | [354](/filings/0001635282-26-000074.md) |
| Current liabilities | $m | [336](/filings/0001635282-25-000029.md) | [293](/filings/0001635282-24-000107.md) | [303](/filings/0001635282-24-000143.md) | [322](/filings/0001635282-24-000173.md) | [325](/filings/0001635282-26-000014.md) | [295](/filings/0001635282-25-000131.md) | [307](/filings/0001635282-25-000190.md) | [275](/filings/0001635282-25-000215.md) | [347](/filings/0001635282-26-000074.md) | [324](/filings/0001635282-26-000042.md) | [312](/filings/0001635282-26-000056.md) | [282](/filings/0001635282-26-000074.md) |
| Total liabilities | $m | [433](/filings/0001635282-25-000029.md) | [388](/filings/0001635282-24-000107.md) | [403](/filings/0001635282-24-000143.md) | [421](/filings/0001635282-24-000173.md) | [439](/filings/0001635282-26-000014.md) | [407](/filings/0001635282-25-000131.md) | [427](/filings/0001635282-25-000190.md) | [380](/filings/0001635282-25-000215.md) | [450](/filings/0001635282-26-000074.md) | [420](/filings/0001635282-26-000042.md) | [401](/filings/0001635282-26-000056.md) | [366](/filings/0001635282-26-000074.md) |
| Long-term debt | $m | [64.2](/filings/0001635282-25-000029.md) | [62.8](/filings/0001635282-24-000107.md) | [68.7](/filings/0001635282-24-000143.md) | [68.0](/filings/0001635282-24-000173.md) | [82.2](/filings/0001635282-26-000014.md) | [81.4](/filings/0001635282-25-000131.md) | [75.6](/filings/0001635282-25-000190.md) | [64.4](/filings/0001635282-25-000215.md) | [63.2](/filings/0001635282-26-000074.md) | [56.4](/filings/0001635282-26-000042.md) | [46.6](/filings/0001635282-26-000056.md) | [41.7](/filings/0001635282-26-000074.md) |
| Current portion of debt | $m | [5.9](/filings/0001635282-25-000029.md) | [5.9](/filings/0001635282-24-000107.md) | [3.1](/filings/0001635282-24-000143.md) | [3.1](/filings/0001635282-24-000173.md) | [3.1](/filings/0001635282-26-000014.md) | [3.1](/filings/0001635282-25-000131.md) | [3.1](/filings/0001635282-25-000190.md) | [3.6](/filings/0001635282-25-000215.md) | [4.0](/filings/0001635282-26-000074.md) | [0.0](/filings/0001635282-26-000042.md) | [0.0](/filings/0001635282-26-000056.md) | [0.0](/filings/0001635282-26-000074.md) |
| Shareholders' equity | $m | [(39.5)](/filings/0001635282-26-000014.md) | [(36.3)](/filings/0001635282-25-000190.md) | [(36.1)](/filings/0001635282-25-000215.md) | [(76.8)](/filings/0001635282-25-000215.md) | [(69.4)](/filings/0001635282-26-000074.md) | [(63.7)](/filings/0001635282-26-000056.md) | [(29.0)](/filings/0001635282-26-000074.md) | [(27.3)](/filings/0001635282-26-000074.md) | [(27.0)](/filings/0001635282-26-000074.md) | [(22.6)](/filings/0001635282-26-000056.md) | [(16.7)](/filings/0001635282-26-000074.md) | [(11.5)](/filings/0001635282-26-000074.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(1.1) d](/filings/0001635282-26-000014.md) | [11.1](/filings/0001635282-25-000131.md) | [6.3 d](/filings/0001635282-25-000190.md) | [(18.5) d](/filings/0001635282-25-000215.md) | [(37.7) d](/filings/0001635282-26-000014.md) | [33.7](/filings/0001635282-26-000042.md) | [(17.8) d](/filings/0001635282-26-000056.md) | [24.7 d](/filings/0001635282-26-000074.md) | [19.6 d](/filings/0001635282-26-000014.md) | [24.5](/filings/0001635282-26-000042.md) | [(1.6) d](/filings/0001635282-26-000056.md) | [(15.2) d](/filings/0001635282-26-000074.md) |
| Capital expenditure | $m | [3.6 d](/filings/0001635282-26-000014.md) | [1.2](/filings/0001635282-25-000131.md) | [0.9 d](/filings/0001635282-25-000190.md) | [0.7 d](/filings/0001635282-25-000215.md) | [0.7 d](/filings/0001635282-26-000014.md) | [0.9](/filings/0001635282-26-000042.md) | [1.8 d](/filings/0001635282-26-000056.md) | [1.2 d](/filings/0001635282-26-000074.md) | [0.7 d](/filings/0001635282-26-000014.md) | [0.6](/filings/0001635282-26-000042.md) | [0.7 d](/filings/0001635282-26-000056.md) | [2.8 d](/filings/0001635282-26-000074.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | [0.0 d](/filings/0001635282-26-000014.md) | not reported | not reported | [0.0 d](/filings/0001635282-25-000215.md) | [0.0 d](/filings/0001635282-26-000014.md) | not reported | not reported | not reported | [3.8 d](/filings/0001635282-26-000014.md) | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [89.1](/filings/0001635282-24-000107.md) | [89.3](/filings/0001635282-24-000143.md) | [89.4](/filings/0001635282-24-000173.md) | [90.6](/filings/0001635282-25-000131.md) | [90.5](/filings/0001635282-25-000190.md) | [90.8](/filings/0001635282-25-000215.md) | [93.3](/filings/0001635282-26-000042.md) | [94.1](/filings/0001635282-26-000056.md) | [95.3](/filings/0001635282-26-000074.md) | [93.9](/filings/0001635282-26-000042.md) | [94.8](/filings/0001635282-26-000056.md) | [96.1](/filings/0001635282-26-000074.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 92,696,000 at 2026-10-27, from the cover of the [10-Q filed 2026-10-29](/filings/0001635282-26-000074.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 16:32 ET. No prices; not investment advice.